Bausch + Lomb introduced the enVista toric IOL for astigmatism correction for European patients at the 2012 ESCRS Congress in Milan.
Bausch + Lomb introduced the enVista toric IOL for astigmatism correction for European patients at the 2012 ESCRS Congress in Milan.
The fenestrated step-vaulted haptics and 56 degrees contact angle enhances rotational stability. A recent clinical trial demonstrated the absolute mean rotation at six-month visit was 3 degrees and mean decentration was 0.28 mm, compared to 0.5 mm with the current market-leading IOL.
Dr Luis Cadarso, Clinica Cadarso, Pontevedra, Spain, said, " The rotational stability of a toric IOL is critical to providing the best possible outcome for a patient. If the lens rotates a patient’s vision will become suboptimal,” said Luis Cadarso, Clinica Cadarso, Pontevedra, Spain. “In my experience, the new enVista TORIC is very stable. Since this lens is also clinically proven to be glistening-free, it allows me to provide better, more consistent vision for my astigmatic patients.”
Dr Cal Roberts, executive vice president and chief medical officer at B+L, commented, "The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary. Together, our unique Advanced Optics technology, clinically proven glistening-free material, and superior rotational stability, deliver optimal outcomes to patients. The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.